Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs reported standalone revenue from operations of Rs 375.31 crore for Q1 FY26 (quarter ended June 30, 2025), down about 4.6% from Rs 393.49 crore in Q1 FY25. Despite the revenue dip, standalone net profit rose roughly 8.7% to Rs 51.22 crore from Rs 47.14 crore, supported by lower material costs and improved operating margins. On the consolidated side, revenue stood at Rs 386.19 crore and net profit at Rs 49.50 crore, though the company itself flagged that these numbers are not comparable with prior periods because Ganesh Polychem became a joint venture from April 1, 2025 and is now accounted for using the equity method. The board also approved the appointment of M/s Mehta and Mehta as Secretarial Auditors for five years starting FY26 and the re-appointment of Ms. Rupal Vora as Non-Executive Independent Director for a second term of three years. The company's stock option scheme was extended to employees of its subsidiary companies, subject to shareholder approval.
Mixed quarter with softer top line but stronger profitability and margin expansion at the standalone level — a positive sign on cost control even as growth slows. Corporate governance changes are routine and unlikely to move the stock, but investors should monitor whether the revenue softness is temporary amid the JV restructuring.